



## SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)  
(Company Registration Number: 201134046D)

---

### ANNOUNCEMENT ON INTERESTED PERSON TRANSACTIONS PURSUANT TO RULE 905(2) OF THE CATALIST RULES

---

*Unless otherwise defined or the context otherwise requires, all capitalised terms used herein bear the same meanings as in the Announcement (as defined below).*

#### 1. INTRODUCTION

The Board of Directors (the “**Board**”) of Singapore Institute of Advanced Medicine Holdings Ltd. (the “**Company**”, together with its subsidiaries, collectively, the “**Group**”) refers to the Company’s announcement dated 28 October 2024 (the “**Announcement**”) relating to the interested person transactions (“**IPTs**”) entered into by the Group pursuant to Chapter 9 of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (the “**Catalist Rules**”). The Board wishes to update the IPTs entered into by the Group pursuant to Chapter 9 of the Catalist Rules, subsequent to the Announcement.

#### 2. DETAILS OF THE INTERESTED PERSON

During the current financial year ending 30 June 2025 (“**FY2025**”), the Group has entered into IPTs with Espeetex Sdn. Bhd. (“**Espeetex**”). Espeetex is an indirect wholly-owned subsidiary of Berjaya Corporation Berhad, which is, in turn, a controlling shareholder of the Company. Berjaya Corporation Berhad, being a controlling shareholder of the Company, is an “interested person” within the meaning defined in Rule 904 of the Catalist Rules. Accordingly, Espeetex, being an associate of Berjaya Corporation Berhad, is an “interested person” vis-à-vis the Company within the meaning defined in Rule 904 of the Catalist Rules.

Berjaya Corporation Berhad is a public company incorporated in Malaysia and listed on the Main Market of Bursa Malaysia Securities Berhad. Espeetex, an indirect wholly-owned subsidiary of Berjaya Corporation Berhad, is also a substantial shareholder of the Company holding approximately 23.67% shareholding interest in the Company.

Please refer to, *inter alia*, paragraph 7 of this announcement, the section entitled “Statistics of Shareholdings” of the Company’s Annual Report 2024 and the section entitled “Interested Person Transactions” of the offer document of the Company dated 2 February 2024 (“**Offer Document**”), for further information relating to Espeetex and Berjaya Corporation Berhad.

### 3. DETAILS OF AND RATIONALE FOR THE IPT

On 27 February 2025, the Company entered into an intercompany loan agreement dated 27 February 2025 with Espeetex (“**Loan Agreement**”) in relation to the grant of loan of an aggregate principal amount of up to S\$6,000,000 by Espeetex to the Company (“**February 2025 Espeetex Loan**”), which is repayable in cash within a period of two years commencing from the date of drawdown of the February 2025 Espeetex Loan.

The February 2025 Espeetex Loan will accrue interest at the rate of 0.02% plus the base lending rate of Malayan Banking Berhad per annum on daily rest, with default interest at the rate of 0.02% plus the base lending rate of Malayan Banking Berhad per annum accruing on all outstanding amounts under the Loan Agreement from the date that it falls due and payable until the date of actual full repayment thereof. Interest in respect of each financial year shall be calculated based on the aggregate outstanding principal amount of the February 2025 Espeetex Loan as at the end of the immediately preceding financial year.

At the Company’s request, Espeetex had agreed to make available the February 2025 Espeetex Loan to the Company, as it may require from time to time to meet its operational expenses and working capital needs. The Board is of the view that the Company’s entry into the Loan Agreement is beneficial to the Group as the February 2025 Espeetex Loan will improve the Group’s cash flow to meet anticipated general working capital requirements (including meeting general overheads, financing requirements and other operating expenses).

### 4. TOTAL VALUE OF ALL IPTS WITH THE INTERESTED PERSON GROUP FOR FY2025

Under Rule 908 of the Catalist Rules, transactions between the Group and Berjaya Corporation Berhad as well as its associates (including Espeetex) (collectively, the “**Interested Person Group**”) are deemed to be transactions with the same interested person, and such transactions during the same financial year will be aggregated.

<b>Name of interested person</b>	<b>Nature of relationship</b>	<b>Aggregate value of all interested person transactions during the financial year under review (excluding transactions less than \$100,000 and transactions conducted under shareholders’ mandate pursuant to Rule 920)</b>	<b>Aggregate value of all interested person transactions conducted under shareholders’ mandate pursuant to Rule 920 (excluding transactions less than \$100,000)</b>
Espeetex	An indirect wholly-owned subsidiary of Berjaya Corporation Berhad, a controlling shareholder of the Company.	S\$2,713,801.58	Not applicable

As at the date of this announcement, the details of all IPTs entered into with the Interested Person

Group for FY2025 (excluding transactions which are less than S\$100,000) are set out below:

<b>Name of Interested Person</b>	<b>Particulars of IPT</b>	<b>Amount at Risk</b>	<b>%<sup>(1)</sup></b>
Espeetex	Interest payable on the intercompany loan agreement dated 1 August 2024 between the Company and Espeetex in relation to the loan of aggregate principal amount of up to S\$2,000,000 granted by Espeetex to the Company, which is repayable upon the maturity date of 30 June 2026	S\$263,060.45	0.32%
Espeetex	Interest payable on the intercompany loan agreement dated 19 August 2024 between the Company and Espeetex in relation to the loan of aggregate principal amount of up to S\$4,000,000 granted by Espeetex to the Company, which is repayable within a period of two years from such drawdown date	S\$540,181.11	0.66%
Espeetex	Interest payable on the August 2023 Espeetex Loan in respect of the extended term of such loan by two years from 31 July 2025 <sup>(2)</sup>	S\$116,254.06	0.14%
Espeetex	Interest payable on the September 2023 Espeetex Loan in respect of the extended term of such loan by two years from 27 September 2025 <sup>(2)</sup>	S\$779,122.44	0.96%
Espeetex	Interest payable on the January 2024 Espeetex Loan in respect of the extended term of such loan by two years from 30 June 2025 <sup>(3)</sup>	S\$181,806.60	0.22%
Espeetex	Interest payable on the February 2025 Espeetex Loan of aggregate principal amount of up to S\$6,000,000 granted by Espeetex to the Company, which is repayable within a period of two years from such drawdown date	S\$833,376.92 <sup>(4)</sup>	1.02%
<b>Total</b>		<b>S\$2,713,801.58</b>	<b>3.32%</b>

**Notes:**

- (1) As a percentage of the Group's latest audited net tangible assets, based on the latest audited consolidated financial statements of the Group as at 30 June 2024, of approximately S\$81,726,688 ("NTA").
- (2) Please refer to, *inter alia*, the Announcement and the sections entitled "Interested Person Transactions" and "General and Statutory Information – Material Contracts" of the Offer Document for further information relating to the August 2023 Espeetex Loan and the September 2023 Espeetex Loan.
- (3) Please refer to the Announcement for further information relating to the January 2024 Espeetex Loan.
- (4) For the purposes of this section, the Interest payable on the February 2025 Espeetex Loan was computed based on the interest rate of 0.02% plus the base lending rate of Malayan Banking Berhad per annum on daily rest (being 6.65% as at the date of this announcement), being an aggregate of

6.67%. In the event that there is any fluctuation in the base lending rate of Malayan Banking Berhad resulting in an increase in the amount at risk of S\$100,000 or more, the Company will make further announcement(s) in relation to the Loan Agreement, as and when appropriate. Please refer to the paragraph 3 of this announcement for further information relating to the terms of the Loan Agreement.

The aggregate value of all IPTs (excluding transactions less than S\$100,000) entered into by the Group with the Interested Person Group for FY2025 is approximately S\$2,713,801.58 as at the date of this announcement, representing approximately 3.32% of the Group's latest audited NTA for the financial year ended 30 June 2024 ("FY2024"). For avoidance of doubt, the value of IPTs set out in the Announcement had been computed against the Group's audited NTA as at 30 June 2023, being approximately S\$44,900,324, which was then the latest audited NTA available at the date of the Announcement.

Save as disclosed above, as at the date of this announcement, there are no other IPTs (excluding transactions less than S\$100,000) entered into by the Group with the Interested Person Group or any other persons for FY2025.

## 5. TOTAL VALUE OF ALL IPTS FOR FY2025

Save as disclosed above, as at the date of this announcement, there are no other IPTs (excluding transactions which are less than S\$100,000) entered into between the Group and all its interested persons during FY2025.

## 6. AUDIT COMMITTEE STATEMENT

The Audit Committee of the Company (save for Dato' Lee Kok Chuan, who has abstained from the deliberation as a Non-Executive and Non-Independent Director of the Company nominated by Berjaya Corporation Berhad), having considered the terms and rationale for the Loan Agreement, is of the view that the Loan Agreement is on normal commercial terms and is not prejudicial to the interests of the Company and its minority shareholders.

## 7. INTERESTS OF DIRECTORS AND CONTROLLING SHAREHOLDERS

As disclosed in the Offer Document, Ms Vivienne Cheng Chi Fan and Dato' Lee Kok Chuan, both of whom are Non-Executive and Non-Independent Directors of the Company, are nominated by Berjaya Corporation Berhad, a controlling shareholder of the Company, to represent its interest on the Board.

For completeness, the following associates of Berjaya Corporation Berhad are deemed to be substantial shareholders or controlling shareholders (as the case may be) of the Company:

Shareholders	Existing Shareholding Interest (%) <sup>(1)</sup>	
	Direct	Deemed
Espeetex <sup>(2)</sup>	23.67	-
Berjaya Leisure (Cayman) Limited <sup>(2)</sup>	14.25	-
Berjaya Land Berhad <sup>(2)</sup>	-	14.25
Berjaya Group Berhad <sup>(2)</sup>	-	38.36
Berjaya Corporation Berhad <sup>(2)</sup>	-	38.36
Tan Sri Dato' Seri Vincent Tan Chee Yioun <sup>(2)</sup>	-	38.40

### Notes:

(1) Based on the existing number of issued and paid-up ordinary shares in the capital of the Company ("Shares") of 1,052,020,642 Shares as at the date of this announcement.

(2) As at the date of this announcement, Berjaya Group Berhad holds 100.00% of the total number of issued shares in the capital of Espeetex and Bizurai Bijak (M) Sdn Bhd ("Bizurai"). Berjaya Group Berhad also has an aggregate interest (direct and indirect) in approximately 64.99% of Berjaya Land Berhad, which in turn holds 100.00% of the total number of issued shares in the capital of Berjaya Leisure (Cayman) Limited. Berjaya Corporation Berhad holds 100.00% of the total number of issued shares in the capital of Berjaya Group Berhad and has an aggregate interest (direct and indirect) in approximately 73.55% of Berjaya Land Berhad. As at the date of this announcement, Tan Sri Dato' Seri Vincent Tan Chee Yioun

Seri Vincent Tan Chee Yioun has an aggregate interest (direct and indirect) in approximately 15.70% of Berjaya Corporation Berhad.

Accordingly, Berjaya Group Berhad, Berjaya Corporation Berhad, and Tan Sri Dato' Seri Vincent Tan Chee Yioun are deemed to have an interest in all the Shares held by Espeetex, Bizurai, and Berjaya Leisure (Cayman) Limited under Section 7 of the Companies Act 1967 of Singapore ("**Companies Act**") and Section 4 of the Securities and Futures Act 2001 of Singapore ("**SFA**"). As at the date of this announcement, Bizurai has a direct interest in 4,600,000 Shares, representing 0.44% shareholding interest in the Company.

Tan Sri Dato' Seri Vincent Tan Chee Yioun is deemed interested in all the Shares held by Espeetex, Bizurai, and Berjaya Leisure (Cayman) Limited as he is a controlling shareholder of Berjaya Corporation Berhad. Tan Sri Dato' Seri Vincent Tan Chee Yioun is also deemed interested in all the Shares held by Convenience Shopping (Sabah) Sdn Bhd ("**CSSB**") under Section 7 of the Companies Act and Section 4 of the SFA. As at the date of this announcement, CSSB, a wholly-owned subsidiary of 7-Eleven Malaysia Holdings Berhad, has a direct interest in 400,000 Shares, representing 0.04% shareholding interest in the Company.

In addition, Berjaya Land Berhad is deemed to have an interest in all the Shares held by Berjaya Leisure (Cayman) Limited under Section 7 of the Companies Act and Section 4 of the SFA.

Save as disclosed above, the Company and its Directors and controlling shareholders are not related to the Interested Person Group.

Save as disclosed above, none of the Directors or controlling shareholders of the Company and their respective associates has any interest, direct or indirect, in the Loan Agreement, other than through their respective shareholdings (if any), employment and/or directorship (as applicable) in the Company.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien  
Executive Director and Chief Executive Officer  
27 February 2025

---

Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").

This announcement has been reviewed by the Sponsor. It has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.